Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 9/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 8/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | EZH2 | Q15910 | 4/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027153 | 1.00 | CSNK2B (0.40) | CSNK2BPIM1PIM3PIM2FLT3 | |
| SCHEMBL2027149 | 1.00 | CSNK2B (0.40) | CSNK2BPIM1PIM3PIM2FLT3 | |
| SCHEMBL1528123 | 0.86 | CSNK2B (0.40) | CSNK2BEZH2HRH4CSNK2A2BCL6 | |
| SCHEMBL1528121 | 0.86 | CSNK2B (0.40) | CSNK2BEZH2HRH4CSNK2A2BCL6 | |
| SCHEMBL12583577 | 0.86 | MAPT (0.45) | CSNK2BPIM1PIM3PIM2CSNK2A2 | |
| SCHEMBL15368789 | 0.85 | CSNK2B (0.41) | CSNK2BEZH2HRH4CSNK2A2BCL6 | |
| SCHEMBL12583588 | 0.84 | MTOR (0.44) | CSNK2BPIM1PIM3PIM2 | |
| SCHEMBL1527885 | 0.82 | CSNK2B (0.42) | CSNK2BHRH4CSNK2A2BCL6CDK2 | |
| SCHEMBL1527888 | 0.82 | CSNK2B (0.42) | CSNK2BHRH4CSNK2A2BCL6CDK2 | |
| SCHEMBL14158332 | 0.81 | CSNK2B (0.41) | CSNK2BHRH4CSNK2A2BCL6CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CDK2, CKS2, CSNK2A1 | CSNK2B 13/4885PIM1 532/4885PIM3 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.